Tridek One, Paris, June 4, 2019 – Tridek-One, a biotech company specialized in the development of products for the treatment of immune disorders, is pleased to announce a first round of funding of € 3 million with leading investors Advent France Biotechnology and Advent Life Sciences.
Menu